Pfizer Inc.
New York, NY 4 processed 13Fs on this site, 2025 Q3 to 2026 Q2
- $170M
- 17 holdings
- 2026 Q2
- −28.9% QoQ
- Top 5 78.9%
AUM over time
Book
| ORIC, Oric Pharmaceuticals | Reduce −11.1% | 4,780,401 | $12.06 | $58M | −595,943 | +$14M | |
| ALLO, Allogene Therapeutics | Hold | 22,032,040 | $2.26 | $50M | — | — | |
| ARVN, Arvinas | Hold | 3,457,815 | $10.10 | $35M | — | — | |
| CELC, Celcuity | Reduce −15.4% | 295,652 | $106.02 | $31M | −53,754 | −$3.5M | |
| ZURA, Zura Bio | Reduce −4.4% | 2,838,913 | $5.93 | $17M | −131,109 | +$1.3M | |
| WVE, Wave Life Sciences | Hold | 1,875,000 | $6.36 | $12M | — | — | |
| PYXS, Pyxis Oncology | Hold | 7,032,770 | $1.31 | $9.2M | — | — | |
| CRBU, Caribou Biosciences | Hold | 4,690,431 | $1.78 | $8.3M | — | — | |
| Spero Therapeutics | Hold | 2,362,348 | $2.33 | $5.5M | — | — | |
| BHVN, Biohaven | Hold | 505,645 | $8.37 | $4.2M | — | — | |
| CRDF, Cardiff Oncology | Hold | 2,411,575 | $1.55 | $3.7M | — | — | |
| ZNTL, Zentalis Pharmaceuticals | Hold | 953,834 | $2.10 | $2M | — | — | |
| NXTC, Nextcure | Reduce −2.7% | 153,354 | $10.01 | $1.5M | −4,292 | −$702K | |
| AGMB, Agomab Therapeutics | New | 75,000 | $10.85 | $814K | +75,000 | +$814K | |
| QTTB, Q32 Bio | Reduce −63.4% | 101,618 | $7.25 | $737K | −176,159 | −$185K | |
| BOLT, Bolt Biotherapeutics | Hold | 31,305 | $4.38 | $137K | — | — | |
| DNA, Ginkgo Bioworks | Hold | 2,928 | $5.93 | $17K | — | — | |
| Senseonics | Hold | 2,171 | $6.56 | $14K | — | — |
Exits / last held
Gone since 2025 Q4, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ANTX, An2 Therapeutics | Exit | 0 | $1.14 | $815K | −715,295 | −$815K |
Filings history
4 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 17 | $170M | −28.9% | 13F-HR | 8/13/2026 | 000007800326000102 |
| 2026 Q1 | 18 | $239M | +1.3% | 13F-HR | 5/12/2026 | 000007800326000064 |
| 2025 Q4 | 18 | $236M | −46.0% | 13F-HR | 2/12/2026 | 000007800326000013 |
| 2025 Q3 | 21 | $437M | — | 13F-HR | 11/13/2025 | 000007800325000161 |
About
Pfizer Inc.
4 processed 13Fs on this site, 2025 Q3 to 2026 Q2
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
- One Up On Wall Street (Lynch), Peter Lynch View on Amazon